Literature DB >> 31788579

Perioperative Management of Uveitic Cataracts.

Judy L Chen1, Pooja Bhat2, Ann-Marie Lobo-Chan2.   

Abstract

Uveitis patients represent a unique subset of the population undergoing cataract surgery and pose several challenges that require special consideration and strategy. Maintenance of disease quiescence for at least three months prior to surgery maximizes postoperative outcomes, though these patients remain at increased risk for pseudophakic cystoid macular edema, which can be refractory to the traditional steroid treatments. In this review, we detail the pillars of preoperative optimization, intraoperative considerations, and postoperative management of uveitic cataracts, with special attention on the evidence surrounding prevention and treatment of refractory postoperative cystoid macular edema.

Entities:  

Keywords:  Uveitic cataracts; pseudophakic macular edema; uveitic macular edema

Year:  2019        PMID: 31788579      PMCID: PMC6884361          DOI: 10.1016/j.yaoo.2019.04.014

Source DB:  PubMed          Journal:  Adv Ophthalmol Optom


  58 in total

1.  Interferon alpha 2b in the treatment of uveitic cystoid macular edema.

Authors:  Nicholas J Butler; Eric B Suhler; James T Rosenbaum
Journal:  Ocul Immunol Inflamm       Date:  2012-04       Impact factor: 3.070

2.  Intravenous 'pulse' methylprednisolone for the treatment of inflammatory cystoid macular oedema.

Authors:  SiehYean Kiew; John V Forrester; Soon-Phaik Chee; Lucia Kuffová
Journal:  Br J Ophthalmol       Date:  2012-09-27       Impact factor: 4.638

3.  Intravitreal triamcinolone for macular oedema: efficacy in relation to aetiology.

Authors:  Torben Lykke Sørensen; Per Haamann; Jørgen Villumsen; Michael Larsen
Journal:  Acta Ophthalmol Scand       Date:  2005-02

4.  Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema.

Authors:  Martin S Spitzer; Focke Ziemssen; Efdal Yoeruek; Katrin Petermeier; Sabine Aisenbrey; Peter Szurman
Journal:  J Cataract Refract Surg       Date:  2008-01       Impact factor: 3.351

5.  Successful treatment of pseudophakic cystoid macular edema with intravitreal bevacizumab.

Authors:  Antonio Barone; Francesco Prascina; Vincenzo Russo; Cristiana Iaculli; Vito Primavera; Giuseppe Querques; Andrea Stella; Nicola Delle Noci
Journal:  J Cataract Refract Surg       Date:  2008-07       Impact factor: 3.351

6.  RESPONSE OF INFLAMMATORY CYSTOID MACULAR EDEMA TO TREATMENT USING ORAL ACETAZOLAMIDE.

Authors:  Kathryn L Pepple; Macklin H Nguyen; Kaivon Pakzad-Vaezi; Kathleen Williamson; Naomi Odell; Cecilia Lee; Thellea K Leveque; Russell N Van Gelder
Journal:  Retina       Date:  2019-05       Impact factor: 4.256

7.  Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group.

Authors:  J Fernando Arevalo; Rafael A Garcia-Amaris; Jose A Roca; Juan G Sanchez; Lihteh Wu; Maria H Berrocal; Mauricio Maia
Journal:  J Cataract Refract Surg       Date:  2007-12       Impact factor: 3.351

8.  Cataract Surgery Outcomes in Uveitis: The Multicenter Uveitis Steroid Treatment Trial.

Authors:  H Nida Sen; Francis M Abreu; Thomas A Louis; Elizabeth A Sugar; Michael M Altaweel; Susan G Elner; Janet T Holbrook; Douglas A Jabs; Rosa Y Kim; John H Kempen
Journal:  Ophthalmology       Date:  2015-10-20       Impact factor: 12.079

Review 9.  Decision-making and management of uveitic cataract.

Authors:  Nicole Shu-Wen Chan; Seng-Ei Ti; Soon-Phaik Chee
Journal:  Indian J Ophthalmol       Date:  2017-12       Impact factor: 1.848

10.  Topical interferon alpha 2b in the treatment of refractory pseudophakic cystoid macular edema.

Authors:  Arash Maleki; Hossein Aghaei; Stacey Lee
Journal:  Am J Ophthalmol Case Rep       Date:  2018-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.